Clinical Trial Update: A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating NovoTTF-200T(P) in combination with gemcitabine and nab-paclitaxel for resectable pancreatic cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• NovoTTF-200T(P)

Snippet

Sponsor: Ashish Manne | Conditions: Pancreatic Adenocarcinoma, Resectable Pancreatic Cancer | Phase 2 | Status: RECRUITING